Christophe Moreno
Université libre de Bruxelles
281 Papers
1.9K Citations
Christophe Moreno is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Medicine & Hepatitis C. The author has an hindex of 53, co-authored 259 publications. Previous affiliations of Christophe Moreno include Free University of Brussels & University of Toronto.
Chat about Author
Papers
•Journal Article
Early liver transplantation for severe alcoholic hepatitis not responding to medical treatment: results of the French-Belgian prospective study QuickTrans
Alexandre Louvet,Julien Labreuche,Christophe Moreno,Claire Vanlemmens,Romain Moirand,Cyrille Feray,Jérôme Dumortier,G.-P. Pageaux,C. Bureau,F Chermak,Christophe Duvoux,Dominique Thabut,Leroy,Nicolas Carbonell,Ephrem Salamé,Rodolphe Anty,Jérôme Gournay,Jean Delwaide,Christine Silvain,Guillaume Lassailly,Sébastien Dharancy,E Nguyen Khac,Didier Samuel,Alain Duhamel,Philippe Mathurin +24 more
5
•Journal Article
Early liver transplantation for severe alcoholic hepatitis not responding to medical treatment: results of the French-Belgian prospective study QuickTrans
Alexandre Louvet,Julien Labreuche,Christophe Moreno,Claire Vanlemmens,Romain Moirand,Cyrille Feray,Jérôme Dumortier,G.-P. Pageaux,C. Bureau,F Chermak,Christophe Duvoux,Dominique Thabut,Leroy,Nicolas Carbonell,Ephrem Salamé,Rodolphe Anty,Jérôme Gournay,Jean Delwaide,Christine Silvain,Guillaume Lassailly,Sébastien Dharancy,Eric Nguyen-Khac,Didier Samuel,Alain Duhamel,Philippe Mathurin +24 more
5
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).
Tarik Asselah,Christophe Moreno,Christoph Sarrazin,Michael Gschwantler,Graham R. Foster,Antonio Craxì,Peter Buggisch,R Ryan,Oliver Lenz,Jane Scott,Gino Van Dooren,I. Lonjon-Domanec,M. Schlag,Maria Buti +13 more
TL;DR: Overall SVR12 rate (66%) was below the target of 80%, indicating that shortening of treatment with simeprevir plus PR to 12 weeks based on very early response is not effective, however, baseline factors associated with higher SVR 12 rates were identified.
•Journal Article
The Disease Burden of Hepatitis C in Belgium : An update of a realistic disease control strategy.
Peter Stärkel,Dominique Vandijck,Wim Laleman,Pierre Van Damme,Christophe Moreno,Sarah Blach,Homie Razavi,Han van Vlierberghe +7 more
TL;DR: Four new scenarios were developed to achieve the goals of near viral elimination and prevention of HCV associated morbidity and mortality by 2026 and 2031 and would provide the most favorable balance of outcomes.
4